Company intelligence / Profile preview

Nectid

Princeton, New Jersey, United Statesnectid.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Nectid has initiated clinical development for drugs targeting autism and pain. Its lead program NFX‑21 is in the clinical stage for nonalcoholic steatohepatitis. The company has a history of patent sales to major pharmaceutical companies and focuses on repurposing known drugs for CNS disorders.

Therapeutic areas: GastroenterologyPsychiatryNeurology
Modalities: Small moleculeDrug delivery platform
Industry: Biotech

Drug pipeline

1 asset

NFX-21

Unknown

Partnerships

Grunenthal GmbH acquired part of the pain patent portfolio from Nectid in March 2010–2012 period. No other major partnerships disclosed publicly.

Beyond the preview

Go deeper on Nectid.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nectid.

Explore the full profile